In jurisdictions where marijuana remains an illegal substance, it is difficult to impose regulations or health warnings to try to limit exposure to second-and third-hand smoke, which raises concerns for public health. In the last 5 years, recreational marijuana has been legalized in 6 jurisdictions: Uruguay, Alaska, Colorado, Oregon, Washington and Washington, DC. In November 2016, 5 additional US states voted on proposals to legalize marijuana; the proposals passed in Nevada, California, Maine and Massachusetts, and failed in Arizona. Canada plans to legalize marijuana in 2018, and it is likely that more US states and jurisdictions will legalize the drug in the coming years. With this changing landscape, there is a need to better understand the public and individual health risks associated with exposure to second-and third-hand marijuana smoke. The objective of this work was to synthesize the available evidence on this topic. This information will be important to support evidence-informed policy and to support patient-care provider conversations to reduce harm.
Methods

Data sources
We conducted a systematic review of published literature on the effects of exposure to second-and third-hand marijuana smoke, searching 6 databases (MEDLINE, the Cochrane Database of Systematic Reviews, Embase, PsychINFO, CINAHL and the HTA database) from their inception to Oct. 17, 2017 . A library and information specialist developed the search strategies. We conducted the search using all MeSH terms referring to marijuana (e.g., ganga, bhang, hashish, pot, shatter, weed) and MeSH terms referring to second-or third-hand marijuana smoke (e.g., exposure, involuntary, passive, second-hand, third-hand). The full MEDLINE search strategy is available in Appendix 1 (available at www.cmajopen.ca/content/5/4/E814/suppl/DC1). We followed the PRISMA guidelines 16 throughout data acquisition and reporting.
Study selection
Abstract review was conducted independently by 2 reviewers (H.H., L.E.D.). To be included, studies had to be human, in vivo or in vitro studies with more than 1 case reported in English or French, and report original, quantitative data. Abstracts were excluded if they failed to meet all the inclusion criteria; thus, all case reports, commentaries, editorials and letters were excluded. Studies included by either reviewer proceeded to full-text review, which was also conducted by 2 independent reviewers (H.H., L.E.D.). Any disagreements between reviewers were resolved through discussion of the full text; if required, a third reviewer (F.C.) was consulted. After full-text review, the reference lists of included studies were searched to ensure no relevant studies were overlooked.
Data extraction
Data extraction was performed by 2 reviewers (H.H., L.E.D.) in 2017 and included details on the design of the intervention, number of experimental trials, length of exposure, participant recruitment methods, number of participants, inclusion criteria and participant characteristics. Three outcomes were extracted: 1) cannabinoids and cannabinoid metabolites in bodily fluids, 2) self-reported psychoactive effects and 3) eye irritation and discomfort.
Quality assessment
We assessed the quality of the included studies in duplicate using the Downs and Black checklist, a 27-item checklist for assessing the methodological quality of both randomized and nonrandomized studies of health care interventions. 17 The checklist has 5 constructs: 1) reporting, 2) external validity, 3) internal validity -bias, 4) internal validity -confounding and 5) power. 17 Studies are assigned a score of 1 or 0 for each criterion, with a higher score indicating higher quality; the maximum score is 28. Each paper was assigned a grade of excellent (24-28 points), good (19-23 points) , fair (14-18 points) or poor (< 14 points).
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Analysis
We categorized records as studies that measured the chemical components of marijuana smoke or those that investigated the immediate effects on people exposed to second-or third-hand marijuana smoke. Based on outcomes reported, the studies that investigated the immediate effects of exposure were further categorized into 3 subcategories: cannabinoids (e.g., tetrahydrocannabinol [THC] ) and metabolites in bodily fluids, impact of ventilation on effects of second-or third-hand smoke exposure and psychoactive effects of passive exposure. We synthesized the findings within each category qualitatively. Synthesis involved reporting aspects of the findings that were similar or, if there were discrepancies between studies, reporting the differences in study design, methods or execution that could account for the differences.
Results
We identified 1701 unique abstracts. Of these, 60 proceeded to full-text review, 15 of which were included in the final data set ( Figure 1 ). The 15 records reported findings from 8 unique studies. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Details of each included study are presented in Table 1 .
All 15 records were experimental studies on the immediate effects of marijuana smoke exposure in humans in a controlled environment. They all followed a similar protocol whereby nonsmokers sat in proximity to people who were actively smoking. Physiological or psychological outcomes were measured after a period of exposure. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] 32, 33 None of the included studies investigated third-hand marijuana smoke.
All included studies assessed short-term (within 24 h of exposure) effects of smoke exposure; none assessed health effects beyond 24 hours. Meta-analysis was not possible owing to heterogeneous outcomes and reporting, and, therefore, the included studies were synthesized narratively.
All of the included studies were of good to poor quality. The average score on quality assessment was 17.8, with a Research range of 13 27 to 22 [22] [23] [24] [25] (the latter being experimental designs with multiple trials completed).
Immediate clinical outcomes from marijuana smoke exposure
Cannabinoids and cannabinoid metabolites in bodily fluids
Oral fluid concentrations of THC were reported in 4 reports from 3 studies. [20] [21] [22] 28 All studies showed THC in the oral fluid of participants who had been exposed to second-hand marijuana smoke.
Blood concentrations of THC were measured in 8 reports from 6 studies. 22, [24] [25] [26] [27] 30, 31, 33 Participants exposed to secondhand marijuana smoke had lower blood concentrations of THC than active smokers; 22, 24, 27, 33 however, there were detectable amounts of THC in the blood samples of those exposed to second-hand smoke. 25, 26, 30, 31 In 1 study in which multiple trials were performed to test marijuana of different THC content (5.3% and 11.3%), there were no significant differences in the blood concentrations of THC and THC metabolites between trial groups. 22 In 13 reports from 9 studies, the investigators assessed THC metabolite concentrations in urine samples. [19] [20] [21] [23] [24] [25] [26] [27] [29] [30] [31] [32] [33] The evidence suggests that a higher percentage of THC content in smoked marijuana results in higher THC metabolite content in urine (Figure 2) . 20, 22, 27 For example, 4 hours after exposure to marijuana with 1.5% THC, 1 of 5 participants had more than the 20 ng/mL threshold for urine testing, and 4 hours after exposure to marijuana with 11.3% THC, all participants had more than 15 ng/mL, with a maximum concentration of cannabinoid metabolites of 28.3 ng/mL in the urine. 23, 33 Records identified through database searching n = 3011
• Cochrane Database of Systematic Reviews n = 12
Additional records identified by hand searching n = 15
Total n = 3026
Included in systematic review n = 15
Excluded n = 45
• Abstract, poster or conference proceeding n = 2 • Not second-or third-hand marijuana smoke exposure n = 30 • Unknown first-hand exposure to marijuana smoke n = 2 • Full text not available n = 2 • Incorrect study design n = 2 • Animal study n = 7
Full-text studies assessed for eligibility n = 60
Excluded n = 1641
Records screened n = 1701
Excluded: duplicates n = 1325
Figure 1: Flow chart of identified records.
In 2 studies, multiple trials were conducted in ventilated and unventilated environments. 19, [22] [23] [24] Ventilation was manipulated by opening a door 19 or altering the air circulation rate in the room. [22] [23] [24] Both urine THC metabolite concentrations and blood THC levels were higher in those exposed to secondhand smoke in an unventilated environment than in a ventilated environment. Other factors that mediated the effects of exposure to second-hand smoke included air volume, number 
Psychoactive effects
In 2 studies, the psychoactive effects reported by participants exposed to second-hand smoke were described. 19, 22, 32 In 1 study, the investigators used a validated measure (Drug Effects Questionnaire), 19 and in the other, a self-reported feeling of "high" was used.
22,32 Those exposed to marijuana with higher THC content reported stronger drug effects (Figure 2) . 22, 32 The same trend was reported in active smokers. 22, 32 These data indicate that active smokers and those exposed to second-hand smoke experience a similar pattern of intoxication; however, the latter consistently report weaker drug effects than active smokers. 22 
Discomfort and eye irritation
In 1 study, participants exposed to second-hand smoke reported discomfort and eye irritation due to smoke in the room. 23 During the experiment, all participants expressed Note: BMI = body mass index, EMIT = enzyme multiplied immunoassay technique, NR = not reported, SD = standard deviation, THC = tetrahydrocannabinol. *Assessed with the use of the Downs and Black checklist, 17 which rates papers on 5 constructs: 1) reporting, 2) external validity, 3) internal validity -bias, 4) internal validity -confounding and 5) power. A total score of 24-28 points = excellent, 19-23 points = good, 14-18 points = fair, less than 14 points = poor. 18 Research discomfort. 23 As a result, active smokers ceased smoking when they otherwise would have continued.
Interpretation
Second-hand exposure to marijuana smoke can lead to cannabinoid metabolites in bodily fluids sufficient for positive results on testing of oral fluids, blood and urine, and can lead to psychoactive effects. There is evidence of a weak doseresponse relation between THC content of cannabis and effects on those exposed to second-hand smoke, including metabolites found in blood and urine, and psychoactive effects. There is evidence that the relation is mediated by environmental factors, including whether the air space is ventilated, volume of air, number of marijuana cigarettes lit at 1 time, potency of the marijuana and number of smokers.
The simulated environments within some of the included studies may not represent "real-world" scenarios. Some studies placed participants in simulated environments where they were exposed to smoke in closed rooms with controlled ventilation systems. In the context of legalization, people may be exposed to second-hand marijuana smoke outside, in parks or in passing on the sidewalk. This type of exposure may not result in cannabinoid metabolites in bodily fluids, as the exposure may be shorter and less intense than in unventilated areas. However, exposure in closed spaces such as in cafés, bars and clubs may occur, depending on the regulations prohibiting smoking in indoor spaces. In addition, exposure in unventilated spaces such as vehicles or small rooms in private homes is still likely to occur. Thus, the observed relation between second-hand smoke exposure and cannabinoid metabolites in bodily fluids is likely to be generalizable to real-world contexts. Marijuana use in enclosed spaces, particularly in the presence of children, older people or people with respiratory illness, should be limited, ideally through public health measures and legislation in jurisdictions where marijuana is legalized.
In some domains, mirroring public health legislation to protect workers and the general public from second-hand tobacco exposure will be appropriate. For example, bylaws forbidding smoking in indoor spaces such as bars and nightclubs and in shared outdoor spaces such as beaches or parks should be considered. Tobacco smoking frameworks may be useful to inform control regulation. Alignment of tobacco and marijuana smoking bylaws, with a coherent policy approach to exposure to smoke of any kind, may result in the most effective public policies.
Evidence suggests that the chemical composition of second-hand marijuana smoke is similar to that of secondhand tobacco smoke, although differences in the concentrations of the components vary. 34, 35 Even in the absence of studies reporting the long-term health effects of passive exposure, clinicians should assess the risk of passive exposure in their patients and advise marijuana users to limit their use to open outdoor spaces where regulations permit, similar to tobacco use.
Using levels of cannabinoid or THC metabolites found in blood or urine samples to determine marijuana use or intoxication is challenging. There is no universal threshold that can differentiate between those who have actively smoked marijuana and are intoxicated, those who have actively smoked marijuana in the past and those who have been exposed to second-hand smoke. In many jurisdictions that have adopted thresholds for THC for drivers, 5.0 ng/mL for blood and 10 ng/mL for urine are common thresholds to indicate intoxication. 36 In the studies included in this review, these levels were present 4-8 hours after exposure in those exposed to second-hand smoke. This raises questions about whether there should be tolerance for people who claim that their positive urine test result is due to second-hand exposure. 37 As more jurisdictions legalize marijuana for recreational use, smokers may feel that use in common public areas or around children is acceptable, and, subsequently, harms associated with second-hand exposure may also increase. In the Figure 2: Urine levels of tetrahydrocannabinol (THC) and metabolites and subjective effects in participants passively exposed to marijuana smoke in an unventilated environment, 4-8 hours after exposure, by THC content.
current state of the literature on second-hand exposure to marijuana smoke, it is difficult for clinicians to prepare to engage with patients in thorough assessments of marijuana exposure as they would with tobacco and for policy-makers to make evidence-based decisions. Future research to inform the development of effective communication tools, prevention strategies and policies to minimize harms to individual users and society is required. Our systematic review did not identify any studies reporting the long-term effects of exposure to second-hand marijuana smoke or the effects of exposure to third-hand smoke. Participants were not followed beyond the experiment, and it is not known how repeated exposure to marijuana smoke may affect health. Given the known harms associated with active marijuana use, such as mental illness, brain developmental changes, respiratory and cardiac disease, and poor prenatal outcomes, 2,38 the long-term impact of passive exposure requires further study. In the absence of evidence, based on the learnings from tobacco, a focus on harm reduction and limiting passive exposure may be prudent.
Limitations
One limit of our search strategy is that studies that were not in English or French were excluded, and the included studies were conducted primarily in anglophone countries. Furthermore, the included records are limited in transferability owing to small samples and the homogeneity of the population studied. The included studies were of good, fair or poor quality; no excellent studies were identified. The addition of excellentquality studies may have improved the robustness of our findings. The body of literature assessing exposure to secondhand marijuana smoke uses an experimental study design that may not be generalizable more broadly. However, it is likely that, under some regulatory conditions, people will be exposed in ways similar to those of the trials, which would enhance the generalizability of the findings to the real world. 37 In addition, the included studies did not investigate effects in people who were repeatedly exposed to second-hand marijuana smoke, and all study participants were exposed for short periods. Exposure would likely be longer and more frequent if people were visiting a location where marijuana smoke was present, and, therefore, the generalizability of the results may be somewhat limited.
Conclusion
Tetrahydrocannabinol metabolites are retained in the body upward of 4 hours, and people report the experience of psychoactive effects after exposure to second-hand smoke. On a molecular level, marijuana smoke has chemical components similar to those of tobacco smoke, although they are present in different amounts. Although this provides support for the biological plausibility of the relation between exposure to secondhand marijuana smoke and negative health outcomes, there is a gap in the literature in this area. If exposure to second-hand marijuana smoke has similar health risks as direct marijuana use, it may be associated with conditions such as respiratory and cardiac disease as well as mental illness. However, highquality research on the long-and short-term health effects of exposure to second-hand marijuana smoke are required to confirm these possible risks. Given the current state of knowledge, coherent policy approaches to exposure to smoke of any kind may result in the most effective harm-reduction policy.
